Summary
The U.S. Food and Drug Administration (FDA) has approved Orzeyful (oveporexton), the first drug to treat a cause of narcolepsy by targeting the orexin pathway. Developed by Takeda, the pill is effective for narcolepsy type 1, helping patients stay awake during the day and reducing cataplexy episodes.